Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMeBAC: Benzylpenicillin vs Cloxacillin in PSSA Bacteraemia
NCT06726395Phase 4Recruiting
- Sponsor
- Region Skåne
- Start
- Mar 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of benzylpenicillin in Staphylococcus aureus bacteremia (SAB) (2 arms), sponsored by Region Skåne. Primary endpoint: Survival at 90 days without any treatment complications. Started Mar 2025; status: recruiting.
02
Drugs
benzylpenicillin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT06726395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726395.